



## Arcturus Therapeutics to Attend Upcoming Investor Conferences

November 26, 2024

SAN DIEGO--(BUSINESS WIRE)--Nov. 26, 2024-- Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences:

### Piper Sandler 36<sup>th</sup> Annual Healthcare Conference (Fireside Chat)

- Tuesday, December 3, 2024 (4:30 p.m. ET)

### Citi's 2024 Global Healthcare Conference (Attending)

- Wednesday, December 4, 2024

### 7<sup>th</sup> Annual Evercore HealthCONx Conference (Fireside Chat)

- Thursday, December 5, 2024 (8:45 a.m. ET)

Webcast links can be found under Investor Relations/Events section of Arcturus' [website](#).

### About Arcturus

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a commercial mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus' pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus' versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (over 400 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit [www.ArcturusRx.com](http://www.ArcturusRx.com). In addition, please connect with us on [Twitter](#) and [LinkedIn](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20241126182447/en/): <https://www.businesswire.com/news/home/20241126182447/en/>

### Arcturus Therapeutics

Public Relations & Investor Relations

Neda Safarzadeh

VP, Head of IR/PR/Marketing

(858) 900-2682

[IR@ArcturusRx.com](mailto:IR@ArcturusRx.com)

Source: Arcturus Therapeutics Holdings Inc.